How to Get Vyleesi (Bremelanotide) in Nevada

Who Qualifies for a Bremelanotide Prescription in Nevada

Bremelanotide is FDA-approved exclusively for premenopausal women diagnosed with acquired, generalized hypoactive sexual desire disorder (HSDD) [1]. The diagnosis requires clinically significant distress related to low sexual desire that is not explained by a co-existing medical condition, relationship factors, medication side effects, or another psychiatric disorder. The FDA label specifies that HSDD must not be attributable to substance use or another mental health condition [2].

Nevada prescribers typically confirm a diagnosis using the Decreased Sexual Desire Screener (DSDS) or the Female Sexual Function Index (FSFI). The FSFI uses a 19-item questionnaire with a desire domain cutoff score of 5 or below suggesting clinically meaningful dysfunction [3]. A prescriber may also perform a physical exam and review medication history, since SSRIs, hormonal contraceptives, and antihypertensives commonly suppress libido.

Premenopausal status is confirmed through menstrual history or lab values. Women who are postmenopausal, pregnant, or breastfeeding are not candidates for this medication per the FDA indication.

How Telehealth Prescribing Works in Nevada

Nevada law permits prescribers to establish a patient-provider relationship via synchronous audio-video telehealth and issue prescriptions, including for controlled and specialty medications [4]. Bremelanotide is not a controlled substance (it is unscheduled by the DEA), which simplifies the telehealth pathway.

A typical telehealth visit for Vyleesi in Nevada follows this sequence: the patient completes an intake questionnaire documenting sexual health history, current medications, blood pressure readings, and menstrual cycle details. The clinician then conducts a live video consultation lasting 15 to 30 minutes. If HSDD criteria are met, the prescriber sends the prescription electronically to a specialty pharmacy or 503A compounder licensed in Nevada.

Nevada's Board of Medical Examiners requires that the telehealth provider hold an active Nevada medical license or be registered through an interstate compact. The Nevada State Board of Pharmacy recognizes prescriptions issued via telehealth as valid for dispensing, provided the prescriber-patient relationship meets statutory standards [5].

Patients in rural Nevada counties (Elko, Humboldt, Pershing, and others without local sexual-medicine specialists) particularly benefit from telehealth access. The state has only 2.3 physicians per 1,000 residents in rural areas compared to 3.8 in Clark County, according to Nevada DHHS workforce data [6].

Required Labs and Pre-Prescription Workup

No specific lab panel is FDA-mandated before initiating bremelanotide. The prescribing information does require a blood pressure measurement before each dose administration because bremelanotide causes a transient increase in systolic pressure (mean increase of 6 mmHg in clinical trials) [2].

Most Nevada clinicians ordering Vyleesi will request baseline labs to rule out organic causes of low desire:

• Thyroid panel (TSH, free T4) to exclude hypothyroidism
• Complete metabolic panel for liver and kidney function
• Prolactin level to rule out hyperprolactinemia
• Testosterone (total and free) to assess androgen status
• CBC if fatigue or anemia is suspected

The Endocrine Society's 2019 guidelines on female sexual dysfunction recommend checking testosterone and DHEA-S before initiating pharmacotherapy for HSDD, as androgen insufficiency may warrant a different treatment approach [7]. Patients with uncontrolled hypertension (systolic ≥160 mmHg or diastolic ≥100 mmHg) or cardiovascular disease should not use bremelanotide per the FDA contraindications [2].

Pharmacy Options: Brand Vyleesi vs. 503A Compounding

Two dispensing pathways exist for Nevada patients. The brand autoinjector (Vyleesi) is dispensed through specialty pharmacies that stock the product. Alternatively, 503A compounding pharmacies licensed by the Nevada State Board of Pharmacy can compound bremelanotide from bulk pharmaceutical-grade powder with a valid patient-specific prescription.

Brand Vyleesi autoinjector: Each carton contains four single-use autoinjectors (1.75 mg/dose). The wholesale acquisition cost exceeds $900 per carton, though manufacturer copay programs may reduce out-of-pocket costs for commercially insured patients. The autoinjector is prefilled and designed for self-administration in the thigh or abdomen.

503A compounded bremelanotide: Nevada-licensed 503A pharmacies compound bremelanotide as a reconstituted subcutaneous injection in multi-dose vials. Pricing typically ranges from $150 to $350 per vial containing 8 to 10 doses, offering significant cost savings over brand. Under FDA section 503A requirements, these pharmacies must compound in response to a patient-specific prescription, use USP-grade ingredients, and comply with state pharmacy board oversight [8].

Nevada does not impose additional restrictions beyond federal 503A rules for compounding bremelanotide. The Nevada State Board of Pharmacy issues resident and nonresident pharmacy licenses, meaning a 503A pharmacy located outside Nevada can ship compounded bremelanotide to a Nevada patient if it holds a valid nonresident pharmacy license.

Insurance Coverage and Prior Authorization in Nevada

Nevada Medicaid does not cover Vyleesi for any indication. Patients enrolled in Medicaid must pursue self-pay or 503A compounding pathways.

Commercial insurers in Nevada (including UnitedHealthcare, Anthem Blue Cross Blue Shield, and Aetna) vary in their formulary placement of Vyleesi. Most plans that cover the drug classify it as a specialty tier (Tier 4 or 5) medication with prior authorization requirements. A 2022 formulary analysis found that fewer than 40% of commercial plans covered bremelanotide without step therapy requirements [9].

Prior authorization documentation typically includes:

• Confirmed HSDD diagnosis with validated screening tool results
• Documentation that the condition causes clinically significant distress
• Trial and failure of at least one non-pharmacologic intervention (e.g., counseling, sex therapy)
• Some plans require prior trial of flibanserin (Addyi) before approving Vyleesi
• Confirmation of premenopausal status
• Blood pressure within acceptable range

Appeal success rates improve when the prescriber includes FSFI scores, a letter of medical necessity, and documentation of specific contraindications to flibanserin (such as alcohol use or hepatic concerns that preclude daily flibanserin dosing). The appeals process in Nevada follows the state's utilization review regulations, with external review available through the Nevada Division of Insurance after internal appeal exhaustion.

Who Can Prescribe Vyleesi in Nevada

Nevada law permits physicians (MD/DO), nurse practitioners (NP/APRN), and physician assistants (PA) to prescribe bremelanotide. Since January 2024, Nevada APRNs with full practice authority can prescribe independently without a collaborative practice agreement after completing 2 years and 2,000 hours of supervised practice [10].

Physician assistants in Nevada prescribe under a collaborative agreement with a supervising physician. The supervising physician need not be physically present but must be available for consultation.

For sexual medicine specifically, relevant specialties that commonly prescribe bremelanotide include gynecology, sexual medicine, endocrinology, and primary care. Psychiatrists may also prescribe when HSDD is identified during treatment for comorbid mood disorders, particularly when SSRIs are contributing to decreased desire.

Clinical Evidence: What the Trials Show

The FDA approved bremelanotide based on two phase 3 randomized controlled trials collectively called RECONNECT (N=1,247 premenopausal women with HSDD) [1]. These 24-week trials compared bremelanotide 1.75 mg subcutaneous injection (used as needed before sexual activity) to placebo.

Primary efficacy results from RECONNECT:

• FSFI desire domain score increased by 0.5 points over placebo (P<0.001)
• Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13 score decreased by 0.7 points versus placebo (P<0.001)
• Approximately 50% of bremelanotide-treated patients reported meaningful improvement versus 36% on placebo
• Mean number of satisfying sexual events increased by 0.5 per month over placebo

The most common adverse effects were nausea (40% in the first dose, declining to 2% by month 4 of use), flushing (20%), headache (11%), and injection site reactions (5%). Nausea severity decreased with repeated dosing. The FDA review noted that 13% of patients discontinued due to adverse events, with nausea as the primary reason [2].

A post-hoc analysis of RECONNECT published in the Journal of Sexual Medicine found that Black women (comprising 15% of the trial population) showed numerically larger improvements in desire scores compared to the overall population, though the trial was not powered for subgroup analysis [11].

Transferring a Prescription to Nevada

Patients relocating to Nevada from another state can transfer an existing Vyleesi prescription. Nevada Board of Pharmacy regulations permit prescription transfers between states for non-controlled medications. The process requires the receiving Nevada pharmacy to contact the originating pharmacy to verify and transfer the prescription record.

For compounded bremelanotide, the prescription cannot technically be "transferred" because 503A prescriptions are patient-specific and pharmacy-specific. The patient's clinician must write a new prescription directed to the Nevada-licensed compounding pharmacy. Many telehealth platforms support this by having the prescriber issue a new Rx to the patient's preferred Nevada pharmacy.

If the patient's out-of-state prescriber is not licensed in Nevada, a new prescriber-patient relationship must be established with a Nevada-licensed provider before continued prescribing.

Timeline: From Consultation to First Dose

The typical timeline for a Nevada patient obtaining Vyleesi breaks down as follows:

Telehealth route (fastest): Initial consultation booking to completed visit takes 2 to 7 days. If labs are needed, add 3 to 5 business days for results. Prescription transmission to pharmacy occurs same day as visit. Specialty pharmacy or 503A compounder ships within 2 to 5 business days. Total: 7 to 17 days from initial booking to medication in hand.

In-person route: Appointment wait times for gynecology or sexual medicine in Las Vegas average 14 to 28 days. Reno and rural areas may extend to 6 weeks. Add lab turnaround and pharmacy processing. Total: 3 to 8 weeks.

If prior authorization is required: Add 5 to 15 business days for initial determination. If denied, peer-to-peer review adds 3 to 7 days. External appeal through Nevada Division of Insurance adds 30 to 45 days.

Patients choosing 503A compounding without insurance involvement bypass prior authorization entirely, often receiving medication within 5 to 10 business days of the initial telehealth visit.

Safety Monitoring and Ongoing Care

After initiating bremelanotide, follow-up typically occurs at 4 to 8 weeks. The prescriber assesses efficacy using repeat FSFI scoring, reviews nausea management (pre-treatment with ondansetron 4 mg orally if nausea is persistent), and confirms blood pressure remains within range.

The FDA label recommends patients self-monitor blood pressure before each injection [2]. Those with a history of cardiovascular disease, uncontrolled hypertension, or who are taking antihypertensives should have more frequent clinical monitoring.

Long-term safety data from the RECONNECT open-label extension (up to 52 weeks of use) showed no new safety signals, no tachyphylaxis, and maintained efficacy in women who continued treatment [1]. Darkening of gingival and facial skin (focal hyperpigmentation) occurred in approximately 1% of patients and was reversible upon discontinuation.

Bremelanotide should not be used within 12 hours of naltrexone administration due to potential interaction (both affect opioid receptor pathways). No clinically significant interactions with SSRIs, hormonal contraceptives, or alcohol have been identified [2].